AbCellera Biologics (NAS:ABCL) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
AbCellera Biologics Forward PE Ratio Related Terms
AbCellera Biologics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics Forward PE Ratio Chart
AbCellera Biologics Annual Data
Trend
Forward PE Ratio
AbCellera Biologics Quarterly Data
2022-03
2022-06
Forward PE Ratio
277.78
52.36
ABCL vs AGIO, KOD, IMNM: Forward PE Ratio Comparison
For the Biotechnology subindustry, AbCellera Biologics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
AbCellera Biologics (ABCL) has a Forward PE Ratio of 0.00 as of Jul. 03, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on AbCellera Biologics and its competitors. According to the industry distribution chart, AbCellera Biologics ranks #999999 out of 355 companies in the Biotechnology industry.
Is AbCellera Biologics' Forward PE Ratio too high?
AbCellera Biologics' current Forward PE Ratio is 0.00. Based on the distribution chart, AbCellera Biologics ranks #999999 out of 355 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AbCellera Biologics has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Forward PE Ratio compare to AGIO and KOD?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #999999 out of 355 companies for Forward PE Ratio. This places AbCellera Biologics in the lower half of its industry. The industry median Forward PE Ratio is 22.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.47, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on AbCellera Biologics and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.51, compared to a current price of $8.11 — trading 47.2% above its estimated fair value. The current Forward PE Ratio is 0.00. AbCellera Biologics' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Forward PE Ratio is 0.00 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $8.11 is trading 47.2% above its estimated GF Value™ of $5.51.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
Forward PE Ratio: 0.00
GF Value™: $5.51 vs. price of $8.11 (47.2% above fair value)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
56GF Score
Get the complete analysis for ABCL
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 